POS0643 RITUXIMAB-ASSOCIATED HYPOGAMMAGLOBULINEMIA IN PATIENTS WITH RHEUMATIC DISEASES: A MULTICENTER RETROSPECTIVE OBSERVATIONAL STUDY
Authors: O. Rusinovich, E. Calvo-Aranda, C. M. Gomez Gonzalez, P. Cardoso Peñafiel, P. Navarro Palomo, M. Machattou, M. Alonso de Francisco, C. Navarro Joven, P. Navarro, M. Cantalejo Moreira, A. J. Diaz Oca, M. Perez Ferro, J. B. Polo Y La Borda, V. Garcia Garcia, M. Fernandez Castro, H. Godoy, C. Merino Argumánez, B. Garcia-Magallon, C. Barbadillo Mateos, L. F. De Villa, C. Isasi Zaragoza, J. Campos Esteban, J. L. Andréu Sánchez, F. Sánchez-Alonso, S. Gonzalo Pascua, J. Sanz
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Rituximab (RTX) is a murine/human chimeric monoclonal antibody directed against the CD20 receptor expressed on pre-B and mature B cells. Rituximab is used effectively in the treatment of different rheumatic diseases, but it can induce hypogammaglobulinemia as a side effect. <h3>Objectives</h3> To analyze the prevalence of hypogammaglobulinemia and its association with infections in patients with rheumatic diseases treated with RTX. <h3>Methods</h3> Multicenter, retrospective, observational study. Patients with rheumatic diseases treated with RTX in 4 centers in Madrid, in which serum immunoglobulin counts were available, were included. Demographic and clinical variables of the sample were analyzed, and changes in immunoglobulin G concentrations during treatment from baseline were assessed. The chi-square test was used to examine the relationship between variables, considering a P value &lt;0.05 as statistically significant. Logistic regression models were used to analyze the association between hypogammaglobulinemia and sample characteristics. <h3>Results</h3> One hundred and seven patients were included: 18 men (16.8%) and 89 women (83.2%), with a mean age of 55.9 (±13.9) years, a mean disease duration of 13.1 (±0.8) years, and a mean age of 51 (±14.4) years at the start of treatment. The most prevalent diagnoses were rheumatoid arthritis (RA) (50.5%), primary Sjogren's syndrome (pSS) (10.3%), and systemic lupus erythematosus (SLE) (10.3%). Fourteen (13%) patients were treated with RTX monotherapy. The rest of the patients received concomitant treatment with other immunomodulators such as corticosteroids (64.5%), methotrexate (29%), hydroxychloroquine (27%), leflunomide (9.3%), sulfasalazine (1.9%), or mycophenolate mofetil (2.8%). Twelve (11.21%) patients developed hypogammaglobulinemia (IgG&lt;600 mg/dl): 6 (50%) had RA, 1 (8.3%) SLE, 1 (8.3%) ANCA vasculitis, 1 (8.3%) leukocytoclastic vasculitis, 1 (8.3%) IgG4-related disease, 1 (8.3%) dermatomyositis, and 1 (8.3%) pSS. Patients with hypogammaglobulinemia had significantly lower mean serum IgG concentrations at the start of treatment (876.3 vs 1249.4 mg/dl; p=0.05). In the multivariate analysis, no variable related to hypogammaglobulinemia was found. Fifty-three (49.5%) patients presented infection, of which 17 (15.9%) were serious infections (those that required admission). The distribution of infection cases by groups (patients with and without hypogammaglobulinemia) is shown in Table 1. No significant differences were found in the development of infections or serious infections between patients with and without hypogammaglobulinemia. Only corticosteroid doses equivalent to ≥7.5 mg/day of prednisone were found as a risk factor for the development of infections (OR 3.48, 95% CI: 1.20-0.11; p=0.02). <h3>Conclusion</h3> Patients with hypogammaglobulinemia had significantly lower mean IgG concentrations at the start of treatment with Rituximab than those who did not develop it. No greater frequency or severity of infections was observed between patients with and without hypogammaglobulinemia. Prednisone equivalent daily dose ≥7.5 mg/day was a risk factor for occurrence of infections. Larger sample size studies are needed to confirm these findings. <h3>Reference: NIL.</h3> <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.